External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
We have previously developed and externally validated a prognostic model of overall survival (OS) in men with metastatic, castration-resistant prostate cancer (mCRPC) treated with docetaxel. We sought to externally validate this model in a broader group of men with docetaxel-naïve mCRPC and in speci...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2023-05, Vol.41 (15), p.2736-2746 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2746 |
|---|---|
| container_issue | 15 |
| container_start_page | 2736 |
| container_title | Journal of clinical oncology |
| container_volume | 41 |
| creator | Halabi, Susan Yang, Qian Roy, Akash Luo, Bin Araujo, John C Logothetis, Christopher Sternberg, Cora N Armstrong, Andrew J Carducci, Michael A Chi, Kim N de Bono, Johann S Petrylak, Daniel P Fizazi, Karim Higano, Celestia S Morris, Michael J Rathkopf, Dana E Saad, Fred Ryan, Charles J Small, Eric J Kelly, William Kevin |
| description | We have previously developed and externally validated a prognostic model of overall survival (OS) in men with metastatic, castration-resistant prostate cancer (mCRPC) treated with docetaxel. We sought to externally validate this model in a broader group of men with docetaxel-naïve mCRPC and in specific subgroups (White, Black, Asian patients, different age groups, and specific treatments) and to classify patients into validated two and three prognostic risk groupings on the basis of the model.
Data from 8,083 docetaxel-naïve mCRPC men randomly assigned on seven phase III trials were used to validate the prognostic model of OS. We assessed the predictive performance of the model by computing the time-dependent area under the receiver operating characteristic curve (tAUC) and validated the two-risk (low and high) and three-risk prognostic groups (low, intermediate, and high).
The tAUC was 0.74 (95% CI, 0.73 to 0.75), and when adjusting for the first-line androgen receptor (AR) inhibitor trial status, the tAUC was 0.75 (95% CI, 0.74 to 0.76). Similar results were observed by the different racial, age, and treatment subgroups. In patients enrolled on first-line AR inhibitor trials, the median OS (months) in the low-, intermediate-, and high-prognostic risk groups were 43.3 (95% CI, 40.7 to 45.8), 27.7 (95% CI, 25.8 to 31.3), and 15.4 (95% CI, 14.0 to 17.9), respectively. Compared with the low-risk prognostic group, the hazard ratios for the high- and intermediate-risk groups were 4.3 (95% CI, 3.6 to 5.1;
< .0001) and 1.9 (95% CI, 1.7 to 2.1;
< .0001).
This prognostic model for OS in docetaxel-naïve men with mCRPC has been validated using data from seven trials and yields similar results overall and across race, age, and different treatment classes. The prognostic risk groups are robust and can be used to identify groups of patients for enrichment designs and for stratification in randomized clinical trials. |
| doi_str_mv | 10.1200/JCO.22.02661 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10414709</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2800149509</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-fca65740283464633a597f640c6c953d2d1f87145acd3c106f932474f662007f3</originalsourceid><addsrcrecordid>eNpVkctuFDEQRS0EIkNgxxp5yYIe_Hb3CqFWeERJBvHeWcZtZ4x67IntaZGP4Fv4CH4s7slDsLJV9_hWuS4ATzFaYoLQy-N-tSRkiYgQ-B5YYE5kIyXn98ECSUoa3NLvB-BRzj8Rwqyl_CE4oBIxxDu2AL-PfhWbgh7hVz36QRcfA4wOavghxfMQc_EGnsbBjnN1NdmkxxF-2qXJT_WRD_DUBvjNlzXs13YTy7oS28vmTP_9M9kqFp2Lnk36ekl7_-ajzb5WQ5mbzLKtajA2PQYPnB6zfXJzHoIvb44-9--ak9Xb9_3rk8bQlpfGGS24ZIi0lAkmKNW8k04wZITpOB3IgF0rMePaDNRgJFxHCZPMCVE3Jh09BK-ufbe7Hxs7GBvqaKPaJr_R6VJF7dX_SvBrdR4nhRHDTKKuOjy_cUjxYmdzURufjR1HHWzcZUXaedsd36MvrlFTP5uTdXd9MFJzhKpGqAhR-wgr_uzf2e7g28zoFcoBmYg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2800149509</pqid></control><display><type>article</type><title>External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer</title><source>MEDLINE</source><source>American Society of Clinical Oncology Online Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Halabi, Susan ; Yang, Qian ; Roy, Akash ; Luo, Bin ; Araujo, John C ; Logothetis, Christopher ; Sternberg, Cora N ; Armstrong, Andrew J ; Carducci, Michael A ; Chi, Kim N ; de Bono, Johann S ; Petrylak, Daniel P ; Fizazi, Karim ; Higano, Celestia S ; Morris, Michael J ; Rathkopf, Dana E ; Saad, Fred ; Ryan, Charles J ; Small, Eric J ; Kelly, William Kevin</creator><creatorcontrib>Halabi, Susan ; Yang, Qian ; Roy, Akash ; Luo, Bin ; Araujo, John C ; Logothetis, Christopher ; Sternberg, Cora N ; Armstrong, Andrew J ; Carducci, Michael A ; Chi, Kim N ; de Bono, Johann S ; Petrylak, Daniel P ; Fizazi, Karim ; Higano, Celestia S ; Morris, Michael J ; Rathkopf, Dana E ; Saad, Fred ; Ryan, Charles J ; Small, Eric J ; Kelly, William Kevin</creatorcontrib><description>We have previously developed and externally validated a prognostic model of overall survival (OS) in men with metastatic, castration-resistant prostate cancer (mCRPC) treated with docetaxel. We sought to externally validate this model in a broader group of men with docetaxel-naïve mCRPC and in specific subgroups (White, Black, Asian patients, different age groups, and specific treatments) and to classify patients into validated two and three prognostic risk groupings on the basis of the model.
Data from 8,083 docetaxel-naïve mCRPC men randomly assigned on seven phase III trials were used to validate the prognostic model of OS. We assessed the predictive performance of the model by computing the time-dependent area under the receiver operating characteristic curve (tAUC) and validated the two-risk (low and high) and three-risk prognostic groups (low, intermediate, and high).
The tAUC was 0.74 (95% CI, 0.73 to 0.75), and when adjusting for the first-line androgen receptor (AR) inhibitor trial status, the tAUC was 0.75 (95% CI, 0.74 to 0.76). Similar results were observed by the different racial, age, and treatment subgroups. In patients enrolled on first-line AR inhibitor trials, the median OS (months) in the low-, intermediate-, and high-prognostic risk groups were 43.3 (95% CI, 40.7 to 45.8), 27.7 (95% CI, 25.8 to 31.3), and 15.4 (95% CI, 14.0 to 17.9), respectively. Compared with the low-risk prognostic group, the hazard ratios for the high- and intermediate-risk groups were 4.3 (95% CI, 3.6 to 5.1;
< .0001) and 1.9 (95% CI, 1.7 to 2.1;
< .0001).
This prognostic model for OS in docetaxel-naïve men with mCRPC has been validated using data from seven trials and yields similar results overall and across race, age, and different treatment classes. The prognostic risk groups are robust and can be used to identify groups of patients for enrichment designs and for stratification in randomized clinical trials.</description><identifier>ISSN: 0732-183X</identifier><identifier>ISSN: 1527-7755</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.22.02661</identifier><identifier>PMID: 37040594</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Docetaxel - therapeutic use ; Humans ; Male ; ORIGINAL REPORTS ; Prognosis ; Proportional Hazards Models ; Prostatic Neoplasms, Castration-Resistant - pathology ; Treatment Outcome</subject><ispartof>Journal of clinical oncology, 2023-05, Vol.41 (15), p.2736-2746</ispartof><rights>2023 by American Society of Clinical Oncology 2023 American Society of Clinical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-fca65740283464633a597f640c6c953d2d1f87145acd3c106f932474f662007f3</citedby><cites>FETCH-LOGICAL-c385t-fca65740283464633a597f640c6c953d2d1f87145acd3c106f932474f662007f3</cites><orcidid>0000-0001-5308-8972 ; 0000-0003-2986-5617 ; 0000-0001-7012-1754 ; 0000-0002-6068-9474 ; 0000-0002-2034-595X ; 0000-0003-4135-2777 ; 0000-0003-2629-672X ; 0000-0002-9454-0096 ; 0000-0001-6165-5797 ; 0000-0003-3938-2627 ; 0000-0002-8102-288X ; 0000-0002-3983-5676 ; 0000-0003-3191-6268 ; 0000-0002-3782-7226</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,781,785,886,3730,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37040594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Halabi, Susan</creatorcontrib><creatorcontrib>Yang, Qian</creatorcontrib><creatorcontrib>Roy, Akash</creatorcontrib><creatorcontrib>Luo, Bin</creatorcontrib><creatorcontrib>Araujo, John C</creatorcontrib><creatorcontrib>Logothetis, Christopher</creatorcontrib><creatorcontrib>Sternberg, Cora N</creatorcontrib><creatorcontrib>Armstrong, Andrew J</creatorcontrib><creatorcontrib>Carducci, Michael A</creatorcontrib><creatorcontrib>Chi, Kim N</creatorcontrib><creatorcontrib>de Bono, Johann S</creatorcontrib><creatorcontrib>Petrylak, Daniel P</creatorcontrib><creatorcontrib>Fizazi, Karim</creatorcontrib><creatorcontrib>Higano, Celestia S</creatorcontrib><creatorcontrib>Morris, Michael J</creatorcontrib><creatorcontrib>Rathkopf, Dana E</creatorcontrib><creatorcontrib>Saad, Fred</creatorcontrib><creatorcontrib>Ryan, Charles J</creatorcontrib><creatorcontrib>Small, Eric J</creatorcontrib><creatorcontrib>Kelly, William Kevin</creatorcontrib><title>External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>We have previously developed and externally validated a prognostic model of overall survival (OS) in men with metastatic, castration-resistant prostate cancer (mCRPC) treated with docetaxel. We sought to externally validate this model in a broader group of men with docetaxel-naïve mCRPC and in specific subgroups (White, Black, Asian patients, different age groups, and specific treatments) and to classify patients into validated two and three prognostic risk groupings on the basis of the model.
Data from 8,083 docetaxel-naïve mCRPC men randomly assigned on seven phase III trials were used to validate the prognostic model of OS. We assessed the predictive performance of the model by computing the time-dependent area under the receiver operating characteristic curve (tAUC) and validated the two-risk (low and high) and three-risk prognostic groups (low, intermediate, and high).
The tAUC was 0.74 (95% CI, 0.73 to 0.75), and when adjusting for the first-line androgen receptor (AR) inhibitor trial status, the tAUC was 0.75 (95% CI, 0.74 to 0.76). Similar results were observed by the different racial, age, and treatment subgroups. In patients enrolled on first-line AR inhibitor trials, the median OS (months) in the low-, intermediate-, and high-prognostic risk groups were 43.3 (95% CI, 40.7 to 45.8), 27.7 (95% CI, 25.8 to 31.3), and 15.4 (95% CI, 14.0 to 17.9), respectively. Compared with the low-risk prognostic group, the hazard ratios for the high- and intermediate-risk groups were 4.3 (95% CI, 3.6 to 5.1;
< .0001) and 1.9 (95% CI, 1.7 to 2.1;
< .0001).
This prognostic model for OS in docetaxel-naïve men with mCRPC has been validated using data from seven trials and yields similar results overall and across race, age, and different treatment classes. The prognostic risk groups are robust and can be used to identify groups of patients for enrichment designs and for stratification in randomized clinical trials.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Docetaxel - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>ORIGINAL REPORTS</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Prostatic Neoplasms, Castration-Resistant - pathology</subject><subject>Treatment Outcome</subject><issn>0732-183X</issn><issn>1527-7755</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkctuFDEQRS0EIkNgxxp5yYIe_Hb3CqFWeERJBvHeWcZtZ4x67IntaZGP4Fv4CH4s7slDsLJV9_hWuS4ATzFaYoLQy-N-tSRkiYgQ-B5YYE5kIyXn98ECSUoa3NLvB-BRzj8Rwqyl_CE4oBIxxDu2AL-PfhWbgh7hVz36QRcfA4wOavghxfMQc_EGnsbBjnN1NdmkxxF-2qXJT_WRD_DUBvjNlzXs13YTy7oS28vmTP_9M9kqFp2Lnk36ekl7_-ajzb5WQ5mbzLKtajA2PQYPnB6zfXJzHoIvb44-9--ak9Xb9_3rk8bQlpfGGS24ZIi0lAkmKNW8k04wZITpOB3IgF0rMePaDNRgJFxHCZPMCVE3Jh09BK-ufbe7Hxs7GBvqaKPaJr_R6VJF7dX_SvBrdR4nhRHDTKKuOjy_cUjxYmdzURufjR1HHWzcZUXaedsd36MvrlFTP5uTdXd9MFJzhKpGqAhR-wgr_uzf2e7g28zoFcoBmYg</recordid><startdate>20230520</startdate><enddate>20230520</enddate><creator>Halabi, Susan</creator><creator>Yang, Qian</creator><creator>Roy, Akash</creator><creator>Luo, Bin</creator><creator>Araujo, John C</creator><creator>Logothetis, Christopher</creator><creator>Sternberg, Cora N</creator><creator>Armstrong, Andrew J</creator><creator>Carducci, Michael A</creator><creator>Chi, Kim N</creator><creator>de Bono, Johann S</creator><creator>Petrylak, Daniel P</creator><creator>Fizazi, Karim</creator><creator>Higano, Celestia S</creator><creator>Morris, Michael J</creator><creator>Rathkopf, Dana E</creator><creator>Saad, Fred</creator><creator>Ryan, Charles J</creator><creator>Small, Eric J</creator><creator>Kelly, William Kevin</creator><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5308-8972</orcidid><orcidid>https://orcid.org/0000-0003-2986-5617</orcidid><orcidid>https://orcid.org/0000-0001-7012-1754</orcidid><orcidid>https://orcid.org/0000-0002-6068-9474</orcidid><orcidid>https://orcid.org/0000-0002-2034-595X</orcidid><orcidid>https://orcid.org/0000-0003-4135-2777</orcidid><orcidid>https://orcid.org/0000-0003-2629-672X</orcidid><orcidid>https://orcid.org/0000-0002-9454-0096</orcidid><orcidid>https://orcid.org/0000-0001-6165-5797</orcidid><orcidid>https://orcid.org/0000-0003-3938-2627</orcidid><orcidid>https://orcid.org/0000-0002-8102-288X</orcidid><orcidid>https://orcid.org/0000-0002-3983-5676</orcidid><orcidid>https://orcid.org/0000-0003-3191-6268</orcidid><orcidid>https://orcid.org/0000-0002-3782-7226</orcidid></search><sort><creationdate>20230520</creationdate><title>External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer</title><author>Halabi, Susan ; Yang, Qian ; Roy, Akash ; Luo, Bin ; Araujo, John C ; Logothetis, Christopher ; Sternberg, Cora N ; Armstrong, Andrew J ; Carducci, Michael A ; Chi, Kim N ; de Bono, Johann S ; Petrylak, Daniel P ; Fizazi, Karim ; Higano, Celestia S ; Morris, Michael J ; Rathkopf, Dana E ; Saad, Fred ; Ryan, Charles J ; Small, Eric J ; Kelly, William Kevin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-fca65740283464633a597f640c6c953d2d1f87145acd3c106f932474f662007f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Docetaxel - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>ORIGINAL REPORTS</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Prostatic Neoplasms, Castration-Resistant - pathology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Halabi, Susan</creatorcontrib><creatorcontrib>Yang, Qian</creatorcontrib><creatorcontrib>Roy, Akash</creatorcontrib><creatorcontrib>Luo, Bin</creatorcontrib><creatorcontrib>Araujo, John C</creatorcontrib><creatorcontrib>Logothetis, Christopher</creatorcontrib><creatorcontrib>Sternberg, Cora N</creatorcontrib><creatorcontrib>Armstrong, Andrew J</creatorcontrib><creatorcontrib>Carducci, Michael A</creatorcontrib><creatorcontrib>Chi, Kim N</creatorcontrib><creatorcontrib>de Bono, Johann S</creatorcontrib><creatorcontrib>Petrylak, Daniel P</creatorcontrib><creatorcontrib>Fizazi, Karim</creatorcontrib><creatorcontrib>Higano, Celestia S</creatorcontrib><creatorcontrib>Morris, Michael J</creatorcontrib><creatorcontrib>Rathkopf, Dana E</creatorcontrib><creatorcontrib>Saad, Fred</creatorcontrib><creatorcontrib>Ryan, Charles J</creatorcontrib><creatorcontrib>Small, Eric J</creatorcontrib><creatorcontrib>Kelly, William Kevin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Halabi, Susan</au><au>Yang, Qian</au><au>Roy, Akash</au><au>Luo, Bin</au><au>Araujo, John C</au><au>Logothetis, Christopher</au><au>Sternberg, Cora N</au><au>Armstrong, Andrew J</au><au>Carducci, Michael A</au><au>Chi, Kim N</au><au>de Bono, Johann S</au><au>Petrylak, Daniel P</au><au>Fizazi, Karim</au><au>Higano, Celestia S</au><au>Morris, Michael J</au><au>Rathkopf, Dana E</au><au>Saad, Fred</au><au>Ryan, Charles J</au><au>Small, Eric J</au><au>Kelly, William Kevin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2023-05-20</date><risdate>2023</risdate><volume>41</volume><issue>15</issue><spage>2736</spage><epage>2746</epage><pages>2736-2746</pages><issn>0732-183X</issn><issn>1527-7755</issn><eissn>1527-7755</eissn><abstract>We have previously developed and externally validated a prognostic model of overall survival (OS) in men with metastatic, castration-resistant prostate cancer (mCRPC) treated with docetaxel. We sought to externally validate this model in a broader group of men with docetaxel-naïve mCRPC and in specific subgroups (White, Black, Asian patients, different age groups, and specific treatments) and to classify patients into validated two and three prognostic risk groupings on the basis of the model.
Data from 8,083 docetaxel-naïve mCRPC men randomly assigned on seven phase III trials were used to validate the prognostic model of OS. We assessed the predictive performance of the model by computing the time-dependent area under the receiver operating characteristic curve (tAUC) and validated the two-risk (low and high) and three-risk prognostic groups (low, intermediate, and high).
The tAUC was 0.74 (95% CI, 0.73 to 0.75), and when adjusting for the first-line androgen receptor (AR) inhibitor trial status, the tAUC was 0.75 (95% CI, 0.74 to 0.76). Similar results were observed by the different racial, age, and treatment subgroups. In patients enrolled on first-line AR inhibitor trials, the median OS (months) in the low-, intermediate-, and high-prognostic risk groups were 43.3 (95% CI, 40.7 to 45.8), 27.7 (95% CI, 25.8 to 31.3), and 15.4 (95% CI, 14.0 to 17.9), respectively. Compared with the low-risk prognostic group, the hazard ratios for the high- and intermediate-risk groups were 4.3 (95% CI, 3.6 to 5.1;
< .0001) and 1.9 (95% CI, 1.7 to 2.1;
< .0001).
This prognostic model for OS in docetaxel-naïve men with mCRPC has been validated using data from seven trials and yields similar results overall and across race, age, and different treatment classes. The prognostic risk groups are robust and can be used to identify groups of patients for enrichment designs and for stratification in randomized clinical trials.</abstract><cop>United States</cop><pub>Wolters Kluwer Health</pub><pmid>37040594</pmid><doi>10.1200/JCO.22.02661</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-5308-8972</orcidid><orcidid>https://orcid.org/0000-0003-2986-5617</orcidid><orcidid>https://orcid.org/0000-0001-7012-1754</orcidid><orcidid>https://orcid.org/0000-0002-6068-9474</orcidid><orcidid>https://orcid.org/0000-0002-2034-595X</orcidid><orcidid>https://orcid.org/0000-0003-4135-2777</orcidid><orcidid>https://orcid.org/0000-0003-2629-672X</orcidid><orcidid>https://orcid.org/0000-0002-9454-0096</orcidid><orcidid>https://orcid.org/0000-0001-6165-5797</orcidid><orcidid>https://orcid.org/0000-0003-3938-2627</orcidid><orcidid>https://orcid.org/0000-0002-8102-288X</orcidid><orcidid>https://orcid.org/0000-0002-3983-5676</orcidid><orcidid>https://orcid.org/0000-0003-3191-6268</orcidid><orcidid>https://orcid.org/0000-0002-3782-7226</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2023-05, Vol.41 (15), p.2736-2746 |
| issn | 0732-183X 1527-7755 1527-7755 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10414709 |
| source | MEDLINE; American Society of Clinical Oncology Online Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Docetaxel - therapeutic use Humans Male ORIGINAL REPORTS Prognosis Proportional Hazards Models Prostatic Neoplasms, Castration-Resistant - pathology Treatment Outcome |
| title | External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-10T09%3A09%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=External%20Validation%20of%20a%20Prognostic%20Model%20of%20Overall%20Survival%20in%20Men%20With%20Chemotherapy-Na%C3%AFve%20Metastatic%20Castration-Resistant%20Prostate%20Cancer&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=Halabi,%20Susan&rft.date=2023-05-20&rft.volume=41&rft.issue=15&rft.spage=2736&rft.epage=2746&rft.pages=2736-2746&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.22.02661&rft_dat=%3Cproquest_pubme%3E2800149509%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2800149509&rft_id=info:pmid/37040594&rfr_iscdi=true |